Blaine M. Hackman Ph.D.

Blaine M. Hackman, Ph.D. currently focuses his practice on U.S. Patent and Trademark Office post-grant proceedings, patent litigation, and patent counseling, and prosecution. Dr. Hackman has represented pharmaceutical and biotechnology clients in Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB). Dr. Hackman has also represented pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and advised on patent issues for numerous transactions. He has also prosecuted patents and counseled clients in transactions in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.

Dr. Hackman has published, presented, and provided insights on intellectual property-related issues, including publications for Reuters on the legacy of Judge Prost’s opinions and dissents related to life sciences patent law, in Law360 on discretionary denials of PTAB petitions with parallel Hatch-Waxman litigations, and in the annual PTAB Bar Association Law Journal on comparing and contrasting expert discovery protections between the PTAB and district courts. Dr. Hackman has also provided perspectives on patent law in interviews for Bloomberg and Law360. His writing has been recognized by the Licensing Executive Society International Journal, les Nouvelles, for publishing the Article of the Month. He has also been recognized as a Rising Star by Super Lawyers in their intellectual property category in 2017-2023.